GSK PLC (GS71.DE) Stock Overview
Europe - FRA:GS71 - GB00BN7SWP63 - Common Stock
GS71.DE Key Statistics, Chart & Performance
The current stock price of GS71.DE is 17.61 EUR. In the past month the price increased by 6.53%. In the past year, price decreased by -9.69%.
GS71.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 46.73 | 611.22B | ||
| LLY.DE | ELI LILLY & CO | 46.29 | 605.45B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.31 | 429.11B | ||
| JNJ.DE | JOHNSON & JOHNSON | 17.77 | 366.31B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 17.75 | 365.97B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.25 | 242.78B | ||
| NOT.DE | NOVARTIS AG-REG | 14.7 | 212.91B | ||
| NOV.DE | NOVO NORDISK A/S-B | 13.95 | 207.09B | ||
| SNW.DE | SANOFI | 10.7 | 197.07B | ||
| SAN.PA | SANOFI | 10.69 | 196.82B | ||
| 1SAN.MI | SANOFI | 10.61 | 195.46B | ||
| 6MK.DE | MERCK & CO. INC. | 10.96 | 180.34B |
Related stock screener links
About GS71.DE
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Company Info
GSK PLC
980 Great West Road
Brentford MIDDLESEX GB
Employees: 68629
Phone: 442080475000
GSK PLC / GS71.DE FAQ
What is the stock price of GSK PLC today?
The current stock price of GS71.DE is 17.61 EUR. The price increased by 1.97% in the last trading session.
What is the ticker symbol for GSK PLC stock?
The exchange symbol of GSK PLC is GS71 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is GS71.DE stock listed?
GS71.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for GSK PLC stock?
31 analysts have analysed GS71.DE and the average price target is 19.22 EUR. This implies a price increase of 9.16% is expected in the next year compared to the current price of 17.61. Check the GSK PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GSK PLC worth?
GSK PLC (GS71.DE) has a market capitalization of 35.48B EUR. This makes GS71.DE a Large Cap stock.
How many employees does GSK PLC have?
GSK PLC (GS71.DE) currently has 68629 employees.
What are the support and resistance levels for GSK PLC (GS71.DE) stock?
GSK PLC (GS71.DE) has a support level at 17.47 and a resistance level at 18.42. Check the full technical report for a detailed analysis of GS71.DE support and resistance levels.
Is GSK PLC (GS71.DE) expected to grow?
The Revenue of GSK PLC (GS71.DE) is expected to grow by 3.27% in the next year. Check the estimates tab for more information on the GS71.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GSK PLC (GS71.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GS71.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GS71.DE, evaluating the profitability, health, valuation and growth aspects
- GSK PLC (GS71.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GSK PLC (GS71.DE) Sales and EPS estimates to see what analysts future expectations are.
- GSK PLC (GS71.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GSK PLC (GS71.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- GSK PLC (GS71.DE) Stock Chart to make your own analysis
- GSK PLC (GS71.DE) Latest news and press-releases to stay up to date.
Does GSK PLC (GS71.DE) stock pay dividends?
GSK PLC (GS71.DE) has a dividend yield of 4.36%. The yearly dividend amount is currently 0.69. Check the full fundamental report for a detailed analysis of GS71.DE dividend history, reliability and sustainability.
When does GSK PLC (GS71.DE) report earnings?
GSK PLC (GS71.DE) will report earnings on 2025-10-29, before the market open.
What is the Price/Earnings (PE) ratio of GSK PLC (GS71.DE)?
The PE ratio for GSK PLC (GS71.DE) is 9.27. This is based on the reported non-GAAP earnings per share of 1.9 and the current share price of 17.61 EUR. Check the full fundamental report for a full analysis of the valuation metrics for GS71.DE.
GS71.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GS71.DE. When comparing the yearly performance of all stocks, GS71.DE is a bad performer in the overall market: 84.34% of all stocks are doing better.
GS71.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GS71.DE. GS71.DE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
GS71.DE Financial Highlights
Over the last trailing twelve months GS71.DE reported a non-GAAP Earnings per Share(EPS) of 1.9. The EPS decreased by -0.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.82% | ||
| ROA | 5.78% | ||
| ROE | 23.14% | ||
| Debt/Equity | 1.03 |
GS71.DE Forecast & Estimates
31 analysts have analysed GS71.DE and the average price target is 19.22 EUR. This implies a price increase of 9.16% is expected in the next year compared to the current price of 17.61.
For the next year, analysts expect an EPS growth of 4.79% and a revenue growth 3.27% for GS71.DE